navyyard.org
Iovance Biotherapeutics Announces New Facility at the Navy Yard to Support U.S. Production of Tumor Infiltrating Lymphocyte Cell Therapy Products - The Navy Yard Blog
Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it has entered into a lease agreement to build an approximately 136,000 square foot commercial-scale production facility at the Philadelphia Navy Yard for commercial and clinical production of autologous TIL products, including its candidate lifileucel. …